Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

434
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
434

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Onychomycosis in Diabetics: A Common Infection with Potentially Serious Complications.

Life (Basel, Switzerland)·2025
Same author

Artificial Intelligence and Large Language Models in the Fight Against Superficial Fungal Infections: Friend or Foe?

Clinical, cosmetic and investigational dermatology·2025
Same author

Understanding the evolving treatment landscape of hidradenitis suppurativa: An analysis of All of Us.

PloS one·2025
Same author

Onychomycosis in special populations.

Future microbiology·2025
Same author

Management and Genetics of Alopecia Areata within the USA: A Cross-Sectional Study of All of Us.

Skin appendage disorders·2025
Same author

A Canadian Algorithm on the Management of Telogen Effluvium.

Journal of cutaneous medicine and surgery·2025

Related Experiment Video

Updated: Jun 9, 2025

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

21.1K

BIMZELX® (Bimekizumab-bkzx) Injection, for Subcutaneous Use.

Aditya K Gupta1,2, Avantika Mann3, Kimberly Vincent4

  • 1Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada.

Skinmed
|October 21, 2024
PubMed
Summary

Bimekizumab significantly improved plaque psoriasis symptoms in Phase 3 trials, achieving high rates of skin clearance. This new treatment option demonstrated strong efficacy and a favorable safety profile in patients with moderate to severe psoriasis.

More Related Videos

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons
10:57

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons

Published on: July 13, 2015

12.6K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.4K

Related Experiment Videos

Last Updated: Jun 9, 2025

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

21.1K
Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons
10:57

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons

Published on: July 13, 2015

12.6K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.4K

Area of Science:

  • Dermatology
  • Immunology
  • Clinical Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin condition affecting millions worldwide.
  • Current treatments for moderate to severe plaque psoriasis include biologics targeting specific inflammatory pathways.
  • There is a need for effective and well-tolerated treatment options for plaque psoriasis.

Purpose of the Study:

  • To evaluate the efficacy and safety of bimekizumab for moderate to severe plaque psoriasis.
  • To compare bimekizumab with placebo, ustekinumab, and adalimumab in randomized controlled trials.

Main Methods:

  • Three Phase 3, randomized, double-blind, vehicle, and comparator-controlled studies (Be Vivid, Be Ready, Be Sure) were conducted.
  • Patients with moderate to severe plaque psoriasis received subcutaneous bimekizumab, placebo, ustekinumab, or adalimumab.
  • Primary endpoints included achieving a 90% improvement in Psoriatic Area and Severity Index (PASI 90) and an Investigator's Global Assessment (IGA) score of 0 or 1 at week 16.

Main Results:

  • Bimekizumab achieved PASI 90 in 85-91% of patients across studies, compared to 5-50% for comparators.
  • IGA 0/1 scores were achieved by 84-93% of patients on bimekizumab, versus 5-57% for comparators.
  • Bimekizumab demonstrated a well-tolerated safety profile with no unexpected findings.

Conclusions:

  • Bimekizumab is a highly effective treatment for moderate to severe plaque psoriasis.
  • Bimekizumab offers significant improvements in skin clearance compared to placebo and existing biologics.
  • The safety profile of bimekizumab supports its use in clinical practice for plaque psoriasis management.